The Scottish Medicines Consortium has published advice accepting the use of Thousand Oaks, Calif.-based Amgen Inc.'s Kyprolis (carfilzomib) in combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The advice takes into account the continuing availability of the Patient Access Scheme agreed or a list price that is equivalent or lower. Read More
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is asking for industry feedback on whether Australia should change its naming mechanisms for biosimilars and biologics and if it should adopt practices of other international regulators. Read More
PERTH, Australia – Melbourne-based biotech Starpharma Ltd. expects to file its rolling NDA with the FDA in the next month following positive phase III results for Vivagel BV for preventing recurrent bacterial vaginosis. Read More
HONG KONG – Glaxosmithkline plc confirmed it will be shutting down operations at its Neuroscience R&D Centre in Shanghai. The U.K.-based pharmaceutical giant will move key programs to the global R&D hub in the U.S. "following a portfolio review and prioritization," as outlined in a statement. Read More
HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. signed a collaborating agreement with the National Cancer Center of Japan to join forces in developing rare cancer cures and genomic medicines. Read More
An Australian study reported in the Aug. 2, 2017, edition of Science Translational Medicine has identified a promising new potential target in preclinical models of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-amplified breast cancer (BC). Read More
